Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Dec;612(7939):354-362.
doi: 10.1038/s41586-022-05489-0. Epub 2022 Nov 30.

Molecular basis for selective activation of DREADD-based chemogenetics

Shicheng Zhang #  1 , Ryan H Gumpper #  1 , Xi-Ping Huang  1   2 , Yongfeng Liu  1   2 , Brian E Krumm  1 , Can Cao  1 , Jonathan F Fay  3 , Bryan L Roth  4
Affiliations

Molecular basis for selective activation of DREADD-based chemogenetics

Shicheng Zhang et al. Nature. 2022 Dec.

Abstract

Designer receptors exclusively activated by designer drugs (DREADDs) represent a powerful chemogenetic technology for the remote control of neuronal activity and cellular signalling1-4. The muscarinic receptor-based DREADDs are the most widely used chemogenetic tools in neuroscience research. The Gq-coupled DREADD (hM3Dq) is used to enhance neuronal activity, whereas the Gi/o-coupled DREADD (hM4Di) is utilized to inhibit neuronal activity5. Here we report four DREADD-related cryogenic electron microscopy high-resolution structures: a hM3Dq-miniGq complex and a hM4Di-miniGo complex bound to deschloroclozapine; a hM3Dq-miniGq complex bound to clozapine-N-oxide; and a hM3R-miniGq complex bound to iperoxo. Complemented with mutagenesis, functional and computational simulation data, our structures reveal key details of the recognition of DREADD chemogenetic actuators and the molecular basis for activation. These findings should accelerate the structure-guided discovery of next-generation chemogenetic tools.

PubMed Disclaimer

References

    1. Urban, D. J. & Roth, B. L. DREADDs (designer receptors exclusively activated by designer drugs): chemogenetic tools with therapeutic utility. Annu. Rev. Pharmacol. Toxicol. 55, 399–417 (2015). - DOI
    1. Roth, B. L. DREADDs for neuroscientists. Neuron 89, 683–694 (2016). - DOI
    1. Roth, B. L. How structure informs and transforms chemogenetics. Curr. Opin. Struct. Biol. 57, 9–16 (2019). - DOI
    1. Wang, L. et al. Use of DREADD technology to identify novel targets for antidiabetic drugs. Annu. Rev. Pharmacol. Toxicol. 61, 421–440 (2021). - DOI
    1. Armbruster, B. N., Li, X., Pausch, M. H., Herlitze, S. & Roth, B. L. Evolving the lock to fit the key to create a family of G protein-coupled receptors potently activated by an inert ligand. Proc. Natl Acad. Sci. USA 104, 5163–5168 (2007). - DOI

Publication types

Substances